ATC code L
ATC code L Antineoplastic and immunomodulating agents is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products.[1]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL.[2]National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
| L Antineoplastic and immunomodulating agents |
|---|
| L01 Antineoplastic agents |
| L02 Endocrine therapy |
| L03 Immunostimulants |
| L04 Immunosuppressants |
|
|
References
- ↑ "ATC/DDD Index 2016: code L". WHO Collaborating Centre for Drug Statistics Methodology.
- ↑ "ATCvet Index 2016: code QL". WHO Collaborating Centre for Drug Statistics Methodology.
| SPs/MIs (M phase) |
| ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA replication inhibitor |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Photosensitizers/PDT | |||||||||||||||||||||||||||||||||||||||||||||||||
| Other |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
| CI monoclonal antibodies ("-mab") |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-kinase inhibitors ("-nib") |
| ||||||||||
| Other |
| ||||||||||
| Endogenous |
| ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exogenous | |||||||||||||||||||||
| Intracellular (initiation) |
| ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||||||||||
| Extracellular |
| ||||||||||||||||||||||
This article is issued from Wikipedia - version of the 1/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.